Clinicopathological Features, Prognostic Impact and Treatment Outcome of EDIL3 and SOX4 Expressions in Endometrial Adenocarcinoma

Abstract

Background: Endometrial cancer (EC) is a common gynecological cancer ranks as fifth cancer worldwide and the tenth common cancer in Egypt. Termed DEL-1 (EGF like repeats and discoid domains 3), is an embryonic endothelial cell protein. EDIL3 was associated with regulation of angiogenesis. SOX (sex-determining region Y-related high-mobility-group box transcription factor). SOX4 expression was altered in many human cancers. This research aimed to study the expression of EDIL3, SOX4 in EC in atrial to explore their relationship with clinicopathological parameters prognostic and treatment outcome.Method: This retrospective study included 50 paraffin blocks of cases of endometrial adenocarcinoma (endometroid type) with different grades which were selected from the archives of the Pathology Department, Zagazig University, Egypt during a period from January 2015 to last of December 2019. The expression of EDIL3, SOX4 was evaluated using immunohistochemistry.Results: 56% of the studied patients were >45 years old. 54% had well-differentiated adenocarcinoma, and 56% absent lymph node metastasis. EDIL3 and SOX4 expression is found in 70% and 84% of the studied patients. A statistically significant relation was detected between EDIL 3 and tumor grade, stage, lympho-vascular invasion (LVI), and lymph node metastasis (P value was 0.001, <0.001, 0.002, and 0.005, respectively). SOX4 was significantly correlated with tumor grade, stage, lymph node metastasis, and LVI (P value was 0.039, 0.002, 0.006, and 0.015, respectively).Conclusion: expressions are associated with advanced clinicopathological parameters, unfavorable prognosis, and poor treatment response.

Keywords

• endometrial neoplasms
• novel markers
• immunohistochemistry
• prognosis